Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
about
HER2 signaling regulates HER2 localization and membrane retention.The role of neratinib in HER2-driven breast cancer.The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.Raman Micro-Spectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells.Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
P2860
Q36331808-475B29AC-2E04-4300-B63D-7E24B763148CQ38664492-098C25F1-5226-42C0-A3AA-2DD36D76D60FQ46301742-1F96C3B0-0673-4ECB-BECD-B3E3E7E6E0A6Q49787645-96E7BC28-DE01-442B-B7A0-25C88709EF1BQ50047476-F0DDEEF3-ACFC-46C1-A4C3-2CE42C985FB7Q50187396-2B251F90-8721-47D5-8C31-11689C940CB1Q52592302-1CBADAB1-B456-4E9B-832E-D52674B22E4AQ58803127-CFDA42DA-C777-4861-8666-02A516D76C77
P2860
Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Neratinib induces ErbB2 ubiqui ...... iation in breast cancer cells.
@en
type
label
Neratinib induces ErbB2 ubiqui ...... iation in breast cancer cells.
@en
prefLabel
Neratinib induces ErbB2 ubiqui ...... iation in breast cancer cells.
@en
P2093
P1433
P1476
Neratinib induces ErbB2 ubiqui ...... iation in breast cancer cells.
@en
P2093
Congcong Liu
Jinrui Zhang
Songshu Meng
Taishu Wang
Xuelin Luan
P304
P356
10.1016/J.CANLET.2016.08.026
P407
P577
2016-09-02T00:00:00Z